TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06157385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Medicine
Description: The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
Study: NCT05499962

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Networking Strategies
Description: Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
Study: NCT05800587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy regimen
Study: NCT05610163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy
Description: undergo sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: undergo sigmoidoscopy
Study: NCT05800587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care chemotherapy regimen
Study: NCT05610163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: undergo biopsy
Study: NCT05212246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod cream
Description: Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Study: NCT05800587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Standard of care chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Standard of care chemotherapy regimen
Study: NCT05212246

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Control Cream
Description: The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Study: NCT05601440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose and schedule will be assigned at enrolment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Monitoring arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: Dose and schedule will be assigned at enrolment
Study: NCT05645523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given in to the vein (IV)
Study: NCT05800587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Standard of care chemotherapy regimen
Study: NCT05826535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy
Study: NCT06048419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Program
Description: Home program for 6 weeks (1 hr and 15 minutes per week)
Study: NCT05137483

Intervention type: OTHER
Intervention: Functional tests
Description: We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.

Intervention type: OTHER
Intervention: Functional tests
Description: We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
Study: NCT06091007

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
Study: NCT04999670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial closure method during caesarean section via pfannenstiel incision.
Description: Comparison of three different methods of fascial closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial closure method during caesarean section via pfannenstiel incision.
Description: Comparison of three different methods of fascial closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial closure method during caesarean section via pfannenstiel incision.
Description: Comparison of three different methods of fascial closure.
Study: NCT06158451

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zinc oxide propolis
Description: Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Modified triple antibiotic paste
Description: Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~* After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~* The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency
Study: NCT04723264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food protocols
Description: Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable.
Study: NCT04873466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme-rich malt extract
Description: Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
Study: NCT05885581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A Grow Well
Description: 1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B Healthy Steps
Description: Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
Study: NCT06500377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn breathing only meditation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn focused attention only meditation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn mindfulness only meditation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn breathing, focused attention, and mindfulness combined meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05360667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus plus Exergame-based multicomponent training program
Description: The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
Study: NCT05917782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
Description: subcutaneous injection of 2 doses on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)
Description: subcutaneous injection of 1 dose on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)
Description: subcutaneous injection of 2 doses on Day 1
Study: NCT05738590

Intervention type: PROCEDURE
Intervention: muscle biopsy
Description: true cut needle biopsy
Study: NCT05526950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: CytoSorb
Description: Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
Study: NCT05371444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training with restriction of the DoF
Description: The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training without restriction of the DoF
Description: The intrevention is based in the training of the upper extremity movements without the restriction of DoF
Study: NCT04975334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: One bolus and one infusion of naloxone
Study: NCT05034055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab / tiragolumab
Description: All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
Study: NCT05427643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study group
Description: dental implant procedure under local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: dental implant procedure under local anesthesia
Study: NCT06074952

Intervention type: OTHER
Group type: OTHER
Intervention: Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)
Description: Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)
Description: Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)
Description: Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
Study: NCT04313972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose naltrexone
Description: 2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
Study: NCT01616602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: Patients were asked to lay on their abdomen for their elective colonoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Position
Description: The traditional left-lateral decubitus position
Study: NCT05755815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrolaminar block
Description: A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal block
Description: before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
Study: NCT05606237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Red Light Therapy Device
Description: The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
Study: NCT04704622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine intranasal injection,2 mg/kg, once, 30 min preoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
Study: NCT01113606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obagi New-Derm System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT05525871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrates and Citrulline Malate
Description: Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Fruit puree
Study: NCT05701215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken orally once daily (400 mg) for 12 months